title: [Use of brachytherapy in the treatment of localized prostate cancer. Preliminary report].
abstract: OBJECTIVE
  We emphasize the good results obtained by authors of the United States of North America and Europe using prostate brachytherapy in the treatment of localized prostate cancer.
  
  
  METHODS
  We report 50 patients with stage T1c-T2c treated during the last twenty one months (September 2000, June 2001). Two groups were made--according to Gleason, PSA, local infiltration and percentage of tumor volume in the Biopsy--in low and high risk patients. We report the methodology used in the surgical procedure.
  
  
  RESULTS
  We found the nadir of PSA was 0.5-1 in seven patients followed during eighteen months, and fifteen patients followed during twelve months. We had a failure in two patients. A reference is made about two patients with previously TURP and one with open prostatectomy, with very good post-operative results. Secondary effects are essentially irritative symptoms, well controlled by medical treatment. Four patients had acute urinary retention, one of them persistent. Normal erections were found in thirty five patients, and partial in fifteen, which had a very good respond to Sildenafil. Four cases had partial incontinence, currently only one persist during sleep.
  
  
  CONCLUSIONS
  We have had very good results during the first twenty one months of treatment of cancer of the prostate with brachytherapy. In our opinion the procedure is a very valid option of treatment for this disease.
authors.affiliation: Policlínica Metropolitana, Caracas, Venezuela.
authors.forename: Carlos
authors.initials: C
authors.lastname: Rodríguez Duarte
authors.forename: Jacobo
authors.initials: J
authors.lastname: Mattout
authors.forename: Otto
authors.initials: O
authors.lastname: Moreira
authors.forename: Reina
authors.initials: R
authors.lastname: Jiménez
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D001918:Brachytherapy / Q000009:adverse effects; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology; D006417:Hematuria / Q000209:etiology; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011687:Purines; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D000068677:Sildenafil Citrate; D013450:Sulfones; D020728:Transurethral Resection of Prostate; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000209:etiology; D014555:Urination Disorders / Q000209:etiology; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D010879:Piperazines; D011687:Purines; D019275:Radiopharmaceuticals; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D017430:Prostate-Specific Antigen